Review: Immune‐Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer
- 3 March 2017
- journal article
- review article
- Published by Wiley in Arthritis & Rheumatology
- Vol. 69 (4), 687-699
- https://doi.org/10.1002/art.40043
Abstract
No abstract availableThis publication has 89 references indexed in Scilit:
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agentsArthritis & Rheumatism, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- TH17 cells in tumour immunity and immunotherapyNature Reviews Immunology, 2010
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cellsThe Journal of Experimental Medicine, 2009
- CTLA4 blockade increases Th17 cells in patients with metastatic melanomaJournal of Translational Medicine, 2009
- T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTORProceedings of the National Academy of Sciences of the United States of America, 2008
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008
- Enhancement of Antitumor Immunity by CTLA-4 BlockadeScience, 1996